What is BlueSemi?
BlueSemi is dedicated to creating non-invasive health tech products designed to analyze six key vital signs. The company's focus on accessible and user-friendly health monitoring solutions positions it within the rapidly expanding digital health market. By leveraging technology to provide critical health insights without invasive procedures, BlueSemi aims to empower individuals and healthcare providers with actionable data for proactive health management.
The company's commitment to innovation in health technology is a key differentiator, addressing a growing global demand for remote and continuous health monitoring solutions.
How much funding has BlueSemi raised?
BlueSemi has raised a total of $69.3M across 2 funding rounds:
Angel/Seed
$300K
Debt
$69M
Angel/Seed (2020): $300K with participation from Samsung Electronics, KLA, Google, and Microsoft
Debt (2021): $69M led by Global Emerging Markets
Key Investors in BlueSemi
Samsung Electronics
Samsung Electronics, a global technology leader, invests in digital health initiatives and innovative solutions, aligning with BlueSemi's mission to advance health tech.
KLA
KLA Corporation, a provider of process control and yield management solutions for the semiconductor and related industries, participates in BlueSemi's funding round.
Google, a subsidiary of Alphabet Inc. focused on organizing the world's information, is an investor in BlueSemi's innovative health technology venture.
What's next for BlueSemi?
With the recent influx of capital, BlueSemi is poised for significant expansion and further product development. The major strategic investment suggests a focus on scaling operations, enhancing its technological capabilities, and potentially broadening its market reach. This enterprise-level backing will likely fuel advancements in its non-invasive vital sign analysis technology, enabling the company to solidify its position in the competitive health tech landscape.
Future endeavors may include strategic partnerships, further research and development into new diagnostic tools, and expanding the application of its technology across various healthcare segments.
